Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma

Liu, Xusheng; Kui, Xue-Yan; Gao, Yan; Chen, Xueqin; Zeng, Jing; Liu, Xiaoyu; Zhang, Yaohua; Pei, Zhijun

doi:10.3389/fgene.2022.835265

Cited by 16 publications

(10 citation statements)

References 70 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In esophageal cancer (ESC), YTHDF1 is highly expressed and correlated with multiple adverse clinical features [ 93 ]. LncRNA-HCP5 directly interacts with YTHDF1 and promotes m6A-modified HK2 mRNA translation, thereby boosting the Warburg effect of ESC cells, and ESC progression [ 73 ].…”

Section: Introductionmentioning

confidence: 99%

The function and clinical implication of YTHDF1 in the human system development and cancer

Ren

Yuan

et al. 2023

Biomark Res

View full text Add to dashboard Cite

YTHDF1 is a well-characterized m6A reader protein that is essential for protein translation, stem cell self-renewal, and embryonic development. YTHDF1 regulates target gene expression by diverse molecular mechanisms, such as promoting protein translation or modulating the stability of mRNA. The cellular levels of YTHDF1 are precisely regulated by a complicated transcriptional, post-transcriptional, and post-translational network. Very solid evidence supports the pivotal role of YTHDF1 in embryonic development and human cancer progression. In this review, we discuss how YTHDF1 influences both the physiological and pathological biology of the central nervous, reproductive and immune systems. Therefore we focus on some relevant aspects of the regulatory role played by YTHDF1 as gene expression, complex cell networking: stem cell self-renewal, embryonic development, and human cancers progression. We propose that YTHDF1 is a promising future cancer biomarker for detection, progression, and prognosis. Targeting YTHDF1 holds therapeutic potential, as the overexpression of YTHDF1 is associated with tumor resistance to chemotherapy and immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

The function and clinical implication of YTHDF1 in the human system development and cancer

Ren

Yuan

et al. 2023

Biomark Res

View full text Add to dashboard Cite

show abstract

“…According to the sum of the correlations of these 385 genes in gastrointestinal cancer, we screened the 30 genes with the strongest correlations, which are RARS1, BTF3, HSPA4, NSA2, HNRNPA1, EIF3M, CCT4, OLA1, UIMC1, G3BP1, NACA, RSL1D1, ETF1, MRPS27, RBM22, CCT8, GEMIN5, LARS1, PA2G4, CDK7, NIFK, RSL24D1, EIF3E, THG1L, INTS13, UBE2D2, RPS23, DIMT1, RIOK2, and TTC27 respectively. Previous studies have reported that overexpression of BTF3, CCT8, CDK7, ELF3M, G3BP1, HSPA4, OLA1, and RSL1D1 can contribute to the occurrence and development of CRC ( Goh et al, 2011 ; Zhou et al, 2019 ; Zhou et al, 2021b ; Liao et al, 2021 ; Zhang et al, 2021 ; Liu et al, 2022a ; Liu et al, 2022b ; Li et al, 2022 ), overexpression of CCT4 and PA2G4 can contribute to the occurrence and development of LIHC( Li et al, 2021a ; Sun et al, 2022 ), overexpression of DIMT1 and HNRNPA1 can contribute to the occurrence and development of STAD ( Liu et al, 2017 ; Zhu et al, 2022 ), and overexpression of EIF3E and UIMC1 can contribute to the ESCA occurrence and development ( Xu et al, 2018 ; Yang et al, 2018 ). Therefore, we believe that these genes have the potential to be called diagnostic and therapeutic targets of gastrointestinal cancer.…”

Section: Discussionmentioning

confidence: 99%

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Liu

Liu²,

Zeng³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: NPM1 is highly expressed in a variety of solid tumors and promotes tumor development. However, there are few comprehensive studies on NPM1 analysis in gastrointestinal cancer.Methods: We used bioinformatics tools to study the expression difference of NPM1 between gastrointestinal cancer and control group, and analyzed the relationship between its expression level and the diagnosis, prognosis, functional signaling pathway, immune infiltration, m6A and cuproptosis related genes of gastrointestinal cancer. At the same time, the expression difference of NPM1 between esophageal carcinoma (ESCA) samples and control samples was verified by in vitro experiments.Results: NPM1 was overexpressed in gastrointestinal cancer. In vitro experiments confirmed that the expression of NPM1 in ESCA samples was higher than that in normal samples. The expression of NPM1 has high accuracy in predicting the outcome of gastrointestinal cancer. The expression of NPM1 is closely related to the prognosis of multiple gastrointestinal cancers. Go and KEGG enrichment analysis showed that NPM1 co-expressed genes involved in a variety of biological functions. NPM1 expression is potentially associated with a variety of immune cell infiltration, m6A and cuproptosis related genes in gastrointestinal cancers.Conclusion: NPM1 can be used as a diagnostic and prognostic marker of gastrointestinal cancer, which is related to the immune cell infiltration and the regulation of m6A and cuproptosis.

show abstract

“…An increasing number of studies have focused on the tumor immune microenvironment ( 36 , 37 ). Pyroptosis regulates the tumor immune microenvironment through various mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma

Deng

Liu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundBladder carcinoma (BLCA) is a heterogeneous disease that makes it difficult to achieve proper individual treatment and predict prognosis. This study aimed to develop a risk score from a new perspective of pyroptosis and guide accurate treatment and prognosis prediction for BLCA.MethodsThe TCGA-BLCA cohort data were downloaded from The Cancer Genome Atlas database. Two external validation cohorts were collected from the Gene Expression Omnibus. Another independent validation cohort (the Xiangya cohort) was recruited from our hospital. The least absolute shrinkage and selector operation (LASSO) algorithm and Cox regression models were used to establish the pyroptosis risk score. Thereafter, we correlated the pyroptosis risk score with prognosis, tumor microenvironment (TME) immune hallmarks, and multiple treatments, including anticancer immunotherapy, chemotherapy, radiotherapy, and targeted therapy.ResultsThe pyroptosis risk score was an independent prognostic predictor of BLCA. We found that the activities of multiple steps of the anticancer immune response cycle, such as the release of cancer cell antigens, CD8 T cell recruitment, and NK cell recruitment, were significantly higher in the high-risk score group than in the low-risk score group. In addition, the infiltration levels of the corresponding tumor-infiltrating immune cells (TIICs), such as CD8 T cells and NK cells, were positively correlated with the pyroptosis risk score. Thus, BLCA with a high-risk score may be associated with inflamed phenotypes. Simultaneously, the expression of multiple immune checkpoints (such as PD-L1, CTLA-4, and PD-1) and enrichment scores of gene signatures positively correlated with immunotherapy response were positively correlated with the pyroptosis risk score. Therefore, patients with a high pyroptosis risk score may be more sensitive to immunotherapy. In addition, patients with high pyroptosis risk scores may be more sensitive to chemotherapeutic drugs, such as cisplatin, docetaxel, and paclitaxel. In addition, the pyroptosis risk score accurately predicted the molecular subtypes of BLCA, which were cross-validated in several independent systems.ConclusionsThis study developed and validated a robust pyroptosis risk score that can predict the clinical outcomes and TME immune phenotypes of BLCA. In summary, the pyroptosis risk score helps drive precision therapy in patients with BLCA.

show abstract

Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma

Cited by 16 publications

References 70 publications

The function and clinical implication of YTHDF1 in the human system development and cancer

The function and clinical implication of YTHDF1 in the human system development and cancer

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma

Contact Info

Product

Resources

About